These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28694927)

  • 1. Effects of glucose-lowering agents on ischemic stroke.
    Avgerinos K; Tziomalos K
    World J Diabetes; 2017 Jun; 8(6):270-277. PubMed ID: 28694927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
    Thompson PL; Davis TME
    Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
    Eleftheriadou I; Grigoropoulou P; Liberopoulos E; Liatis S; Kokkinos A; Tentolouris N
    Curr Med Chem; 2018; 25(13):1549-1566. PubMed ID: 28554326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular safety outcomes of new antidiabetic therapies.
    LeBras MH; Barry AR; Koshman SL
    Am J Health Syst Pharm; 2017 Jul; 74(13):970-976. PubMed ID: 28483748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
    Savarese G; D'Amore C; Federici M; De Martino F; Dellegrottaglie S; Marciano C; Ferrazzano F; Losco T; Lund LH; Trimarco B; Rosano GM; Perrone-Filardi P
    Int J Cardiol; 2016 Oct; 220():595-601. PubMed ID: 27390996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose Cotransporter 2 Inhibitors and Ischemic Stroke.
    Milonas D; Tziomalos K
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):134-138. PubMed ID: 29412119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
    Ovalle F
    Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ
    Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
    Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
    Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diabetes Mellitus Type 2: Recent Publications and New Drugs].
    Elbelt U
    Dtsch Med Wochenschr; 2018 Jun; 143(11):772-776. PubMed ID: 29807374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.
    Nassif ME; Kosiborod M
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S12-S19. PubMed ID: 31741435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus.
    Asleh R; Sheikh-Ahmad M; Briasoulis A; Kushwaha SS
    Heart Fail Rev; 2018 May; 23(3):445-459. PubMed ID: 29270818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidiabetic drugs and stroke risk. Current evidence.
    Castilla-Guerra L; Fernandez-Moreno MDC; Leon-Jimenez D; Carmona-Nimo E
    Eur J Intern Med; 2018 Feb; 48():1-5. PubMed ID: 28939005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.
    Shin JI
    Curr Diab Rep; 2019 Jul; 19(8):54. PubMed ID: 31286271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.
    Papagianni M; Tziomalos K
    Hippokratia; 2015; 19(3):195-9. PubMed ID: 27418775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidiabetic treatment, stroke severity and outcome.
    Magkou D; Tziomalos K
    World J Diabetes; 2014 Apr; 5(2):84-8. PubMed ID: 24748923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.